Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins
Yuantao Fu, Yanzhi Zhang, Haiying Sun
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113853-113853
Closed Access | Times Cited: 17

Showing 17 citing articles:

A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles
Hafiz Akbar Ali, Yalan Li, Akram Hafiz Muhammad Bilal, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 31
An updated patent review of BRD4 degraders
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
Combination of microtubule targeting agents with other antineoplastics for cancer treatment
Tingting Liang, Lu Lu, Xueting Song, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188777-188777
Closed Access | Times Cited: 20
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 529-545
Closed Access | Times Cited: 4
Discovery of a potent, orally available furopyridine derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor
Shuichi Hagihara, Kouhei Ishizawa, Manami Kikuchi, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 109, pp. 129848-129848
Closed Access | Times Cited: 3
BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors
Junhua Li, Cheng Zhang, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5760-5799
Closed Access | Times Cited: 15
Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
Xiyao Shi, Ying Wang, Longhui Zhang, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 14
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
Lin Zhao, Hongjie Guo, Xi Chen, et al.
European Journal of Pharmacology (2022) Vol. 927, pp. 175071-175071
Closed Access | Times Cited: 13
Hit me with your best shot: Integrated hit discovery for the next generation of drug targets
Sajda Ashraf, J. Henry Blackwell, Geoffrey A. Holdgate, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 10, pp. 104143-104143
Closed Access | Times Cited: 2
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432
P. G. Humphreys, Niall A. Anderson, Paul Bamborough, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15174-15207
Open Access | Times Cited: 12
From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors
Mladen Koravović, Anand Mayasundari, Gordana Tasić, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115246-115246
Open Access | Times Cited: 4
Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor
Shuichi Hagihara, Kouhei Ishizawa, Kana Soga, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 109, pp. 129849-129849
Closed Access | Times Cited: 1
Development and Evaluation of [11C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging
Yanli Wang, Yongle Wang, Yulong Xu, et al.
ACS Omega (2024)
Open Access | Times Cited: 1
BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease
Zonghui Ma, Andrew A. Bolinger, Irina V. Pinchuk, et al.
Advances in pharmacology (2024), pp. 203-236
Closed Access | Times Cited: 1
Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses
Chunshan Liu, Inmaculada Rioja, Ali Bakr, et al.
International Journal of Cancer (2022) Vol. 151, Iss. 2, pp. 275-286
Open Access | Times Cited: 7
Advancements and Challenges in Tuberculosis Drug Discovery: A Comprehensive Overview
Puja Kumari Agnivesh, Arnab Roy, Shashikanta Sau, et al.
Microbial Pathogenesis (2024) Vol. 198, pp. 107074-107074
Closed Access
Page 1

Scroll to top